Positively Aware Vosevi

Vosevi

sofosbuvir/velpatasvir/voxilaprevir, or SOF/VEL/VOX

Not FDA approved for use in co-infection, but may be considered.
Genotype
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

Standard Dose

One tablet once daily with food. Each tablet contains 400 mg of sofosbuvir, 100 mg of velpatasvir, and 100 mg of voxilaprevir.

Sofosbuvir-based regimens are not recommended in people with creatinine clearance (CrCl) less than 30 mL/min. NS3/4A protease inhibitors, such as voxilaprevir, are not recommended in patients with moderate or severe liver impairment (Child-Pugh B/C), which is also called decompensated cirrhosis. Using Vosevi in decompensated cirrhosis may cause significantly higher amounts of voxilaprevir in the blood and may increase ALT (liver enzyme).

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose.

Not FDA approved for use in co-infection, but may be considered.

BLACK BOX WARNING

Before starting treatment with any direct-acting antiviral (DAA), including Vosevi, patients should take a blood test to check for hepatitis B (HBV) infection. HBV infection could get worse or reactivate during or after DAA treatment, potentially leading to serious liver problems, including liver failure or death. Patients with current or past HBV infection should be monitored during HCV DAA treatment, and some may need to take HBV treatment. See HBV Reactivation for more information and consult your medical provider.

Manufacturer

Gilead Sciences

AWP

$29,904 / month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information